# CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

> **NCT05122546** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 31 (actual)

## Conditions studied

- Advanced Clear Cell Renal Cell Carcinoma
- Advanced Papillary Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma
- Advanced Sarcomatoid Renal Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Papillary Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Metastatic Sarcomatoid Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Unresectable Clear Cell Renal Cell Carcinoma
- Unresectable Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib S-malate
- **DRUG:** Clostridium butyricum CBM 588 Probiotic Strain
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT05122546
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-01
- **Primary completion:** 2027-01-12
- **Final completion:** 2027-01-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05122546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05122546, "CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05122546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*